Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01507441|
Recruitment Status : Completed
First Posted : January 10, 2012
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies DNA samples from patients with Down syndrome and acute myeloid leukemia treated on COG-AAML0431 clinical trial.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: gene mapping Genetic: microarray analysis Genetic: mutation analysis Genetic: nucleic acid sequencing Other: laboratory biomarker analysis|
- To identify new genetic abnormalities associated with acute myeloid leukemia (AML) in patients with Down syndrome through whole-genome sequencing.
OUTLINE: This is a multicenter study.
Extracted DNA and RNA from cryopreserved specimens are analyzed for genomic sequencing, gene mutation, and microarray analysis.
|Study Type :||Observational|
|Estimated Enrollment :||10 participants|
|Official Title:||Whole Exon Sequencing of Down Syndrome Acute Myeloid Leukemia|
|Study Start Date :||February 2012|
|Actual Primary Completion Date :||May 2016|
- Identification of unique mutations through whole-genome sequencing
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01507441
|Principal Investigator:||Jeffrey Taub, MD||Children's Hospital of Michigan|